Skip to main content
. 2014 Jul 3;54(12):1407–1420. doi: 10.1002/jcph.352

Figure 1.

Figure 1

Trial design. CLCR, creatinine clearance; PK, pharmacokinetic; R, rivaroxaban; tid, three times daily.